CMS Budget Plan: $1 Bil. Increase For Administrative Activities Is New, But Drug Policy Proposals Are Old
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS budget plan reprises Medicare drug rebates for dual eligibles, eliminating brand/generic patent settlements and other unsuccessful Rx proposals.
You may also be interested in...
Biologics Exclusivity: GPhA Making Last Stand In Pacific
GPhA, AARP oppose Trans-Pacific Partnership requirement that biologics receive 12 years of exclusivity in part because they don’t want Congress to be unable to change it later.
Amid Uncertainties, Acorda Preps For Next Phase Of ACA: An Interview With Managed Markets Head Kent Rogers
With nine months to go before key aspects of the Affordable Care Act are implemented, Acorda Therapeutics’ head of managed markets, Kent Rogers, says he, like everyone, is ‘learning.” Acorda expects to have a game plan ready by mid-summer on how it will adapt its commercial strategy to ACA-initiated changes. Rogers also points out that the company may be less affected than others in the near term because Medicare already covers the majority of patients who take its multiple sclerosis drug Ampyra.
IPAB Raised At Debate, But Romney Advisor Skeptical Board Will Meet Even If Obama Wins
Strict conflict-of-interest restrictions will make it very challenging to get people confirmed to serve on the Independent Payment Advisory Board established under the 2010 health reform law, according to a top health care advisor to Mitt Romney. IPAB was addressed in the Oct. 3 presidential debate.